AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Lab Animals.
Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.
Lab Animals Industry Benchmarks
The average annual savings achieved in Lab Animals category is 8.17%
The industry average payment terms in Lab Animals category for the current quarter is 68.8 days
Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™
Category Strategy and Flexibility
Price per Unit Competitiveness
Minimum Order Quality
The World’s first Digital Market Analyst
The World’s first Digital Market Analyst
Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions
Lab Animals Suppliers
Find the right-fit lab animals supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.
Use the Lab Animals market, supplier and price information for category strategy creation and Quaterly Business Reviews (QRBs)
Lab Animals market report transcript
Lab Animals Global Market Outlook
There is an Increase in demand for effective animal model to validate efficacy and non toxicity of drugs and vaccines in the pipeline
Large pharmaceuticals are outsourcing the service to two or three suppliers and using niche players wherever necessary based on their study requirements
The focus is on 3R (Replace, Reduce, Refine) principle and pushing towards novel technology therapeutic models, and alternatives to non-animal models
Impact of COVID-19 on Lab Animals Industry
The COVID-19 pandemic has created an unprecedented global public health challenge. It has also expressed a favorable influence on the animal model market for vaccine and antiviral medication research and development. Since early 2021, post pandemic recovery is highly prevalent in the animal market and is likely to provide CROs with additional prospects.
Modified Mouse Models: COVID-19 rodent models, particularly humanised ACE2 (hACE2) mice, which express humanised ACE2 in the airway and other epithelia and develop a deadly SARS-CoV infection, are in high demand. This model is currently used for vaccine toxicity and efficacy evaluation and also to tests drugs to combat the pandemic
Increased Funding and Investment: Many governments and scientific research institutions are likely to expand research funding for vaccines and therapies for contagious diseases, like COVID-19
Demand of Suppliers: Demand of cell therapy and immuno-oncology screening Models have increased in the APAC region, due to expanding R&D facilities in the low cost regions
Procurement-Centric Five Forces Analysis on Lab Animals Industry
The lab animals market is a highly fragmented supply chain, giving sponsors high bargaining power. Service providers, on the other hand, provide services and collaborative work environment to stand out.
The number of raw material suppliers and their product quality have significantly been increasing
With the increase in outsourcing penetration rates by big pharmaceutical players, supplier power would increase from the currently low-to-medium level in the next few years
Suppliers tend to have moderate product differentiation and distribution channels
Barriers to New Entrants
The entry barrier would remain high, due to high economics of scale, investment cost, and stringent government regulatory mandate and legal barriers
Intensity of Rivalry
Industrial competition is expected to further increase, with new players and improved product differentiation inflow into the market
Supplier capabilities, strategies and innovations are growing with the demand of animals for testing
Threat of Substitutes
Threat of substitutes is moderately high in the market, as alternate testing methods are gaining traction, due to ethical and animal rights regulations in many European countries to replace in-vivo testing methodologies. Product differentiation and ease of substitution are extremely high
Pharma’s buying power will remain moderately high, as the number of buyers is steadily increasing with increased purchase quantity
CROs are also expecting a good volume of business from small Biotech companies in the next 1–2 years, due to the increase in venture funding for small Biotechs
Product dependency and backward integration are moderate on the buyer’s side